Literature DB >> 24583618

Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Andrew J Levine1, Stella E Panos, Steve Horvath.   

Abstract

The Human Genome Project, coupled with rapidly evolving high-throughput technologies, has opened the possibility of identifying heretofore unknown biological processes underlying human disease. Because of the opaque nature of HIV-associated neurocognitive disorder (HAND) neuropathogenesis, the utility of such methods has gained notice among NeuroAIDS researchers. Furthermore, the merging of genetics with other research areas has also allowed for application of relatively nascent fields, such as neuroimaging genomics, and pharmacogenetics, to the context of HAND. In this review, we detail the development of genetic, transcriptomic, and epigenetic studies of HAND, beginning with early candidate gene association studies and culminating in current "omics" approaches that incorporate methods from systems biology to interpret data from multiple levels of biological functioning. Challenges with this line of investigation are discussed, including the difficulty of defining a valid phenotype for HAND. We propose that leveraging known associations between biology and pathology across multiple levels will lead to a more reliable and valid phenotype. We also discuss the difficulties of interpreting the massive and multitiered mountains of data produced by current high-throughput omics assays and explore the utility of systems biology approaches in this regard.

Entities:  

Mesh:

Year:  2014        PMID: 24583618      PMCID: PMC3947559          DOI: 10.1097/QAI.0000000000000069

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  227 in total

Review 1.  A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.

Authors:  Stephanie D Kraft-Terry; Shilpa J Buch; Howard S Fox; Howard E Gendelman
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

2.  Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue.

Authors:  K Selmaj; C S Raine
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation.

Authors:  W W Agace; A Amara; A I Roberts; J L Pablos; S Thelen; M Uguccioni; X Y Li; J Marsal; F Arenzana-Seisdedos; T Delaunay; E C Ebert; B Moser; C M Parker
Journal:  Curr Biol       Date:  2000-03-23       Impact factor: 10.834

Review 4.  Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration.

Authors:  R L Nosheny; I Mocchetti; A Bachis
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

5.  The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge.

Authors:  Nunzio Pomara; Kenneth D Belzer; Raul Silva; Thomas B Cooper; John J Sidtis
Journal:  Psychopharmacology (Berl)       Date:  2008-07-31       Impact factor: 4.530

Review 6.  Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system.

Authors:  Italo Mocchetti; Rachel L Nosheny; Gianluigi Tanda; Ke Ren; Edwin M Meyer
Journal:  Ann N Y Acad Sci       Date:  2007-12       Impact factor: 5.691

7.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology.

Authors:  James A Mortimer; David A Snowdon; William R Markesbery
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

Review 9.  The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders.

Authors:  Andrew J Levine; Elyse J Singer; Paul Shapshak
Journal:  AIDS Behav       Date:  2008-02-09

10.  Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders.

Authors:  Alejandra Borjabad; Susan Morgello; Wei Chao; Seon-Young Kim; Andrew I Brooks; Jacinta Murray; Mary Jane Potash; David J Volsky
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

View more
  14 in total

Review 1.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

2.  COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.

Authors:  Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

3.  Transcriptome analyses identify key cellular factors associated with HIV-1-associated neuropathogenesis in infected men.

Authors:  Narasimhan J Venkatachari; Siddhartha Jain; Leah Walker; Shalmali Bivalkar-Mehla; Ansuman Chattopadhyay; Ziv Bar-Joseph; Charles Rinaldo; Ann Ragin; Eric Seaberg; Andrew Levine; James Becker; Eileen Martin; Ned Sacktor; Velpandi Ayyavoo
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

4.  Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders.

Authors:  Andrew J Levine; Austin Quach; David J Moore; Cristian L Achim; Virawudh Soontornniyomkij; Eliezer Masliah; Elyse J Singer; Benjamin Gelman; Natasha Nemanim; Steve Horvath
Journal:  J Neurovirol       Date:  2015-12-21       Impact factor: 2.643

5.  Iron-regulatory genes are associated with Neuroimaging measures in HIV infection.

Authors:  Christine Fennema-Notestine; Tricia A Thornton-Wells; Todd Hulgan; Scott Letendre; Ronald J Ellis; Donald R Franklin; Albert M Anderson; Robert K Heaton; Cinnamon S Bloss; Igor Grant; Asha R Kallianpur
Journal:  Brain Imaging Behav       Date:  2020-10       Impact factor: 3.978

6.  A candidate gene study of intermediate histopathological phenotypes in HIV-associated neurocognitive disorders.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Eliezer Masliah; Janet S Sinsheimer; Sarah S Ji; Steve Horvath; Elyse J Singer; Asha Kallianpur; David J Moore
Journal:  J Neurovirol       Date:  2020-05-11       Impact factor: 2.643

7.  No reliable gene expression biomarkers of current or impending neurocognitive impairment in peripheral blood monocytes of persons living with HIV.

Authors:  Austin Quach; Steve Horvath; Natasha Nemanim; Dimitrios Vatakis; Mallory D Witt; Eric N Miller; Roger Detels; Peter Langfelder; Paul Shapshak; Elyse J Singer; Andrew J Levine
Journal:  J Neurovirol       Date:  2018-03-26       Impact factor: 2.643

8.  Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Cristian L Achim; Eliezer Masliah; Benjamin B Gelman; Janet S Sinsheimer; Elyse J Singer; David J Moore
Journal:  J Neurovirol       Date:  2015-12-04       Impact factor: 2.643

9.  Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.

Authors:  Mariluz Araínga; Dongwei Guo; Jayme Wiederin; Pawel Ciborowski; JoEllyn McMillan; Howard E Gendelman
Journal:  Retrovirology       Date:  2015-01-22       Impact factor: 4.602

Review 10.  Host genetic factors predisposing to HIV-associated neurocognitive disorder.

Authors:  Asha R Kallianpur; Andrew J Levine
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.